Member Info for Bella6532

The US has dosed 3rd Patient in C1 in the US...how many patients in a cohort?

Go ahead for UK just given so when will first patient be dosed and will UK Cohorts have same num ber of patients?

I think In parallel just means they won't have to wait for the US 2W trial to finish and then start the UK trial...the US will continue and the UK will start when ready and both will run at the same time for a period (assuming the US trial will finish first...

HI GMCC...nice to see you again...thanks for that post...couldn't agree more.

and this is why the AIM market was created so that PI's could get in on the early stage investment action which once was only available to II's..

'For investors in micro, small, and mid-cap companies, monitoring IP growth can help them spot early investment opportunities and bargain stocks. That's why IP valuation is an important stock investment tool.'

D-Geeman....undersubscribed...Oh! Really!!!!...

'The REX Offer was limited to an aggregate value of £6.8 million and received total applications in excess of this amount.

WelshFalcon...'Don't forget this phrase will encompass not only those 'warheads' currently approved and in use (with high toxicity and consequent restrictive dosing) but a whole host of 'warheads' where BP has invested large sums and which have failed due to toxicity issues.

The latter can be revived and their trials restarted. An opportunity for BP to recoup/capitalise on currently lost investments.'

Exactly, and the latter is an obvious target and could easily generate a deal or two...

Interesting RNS...it appears to answer a lot of the questions rolling around on here over the past few weeks...not all, but several.

B2HS2L...'I'd be interested to know the date the first patient was drugged, it may have been a while ago.'...Why? what will it help you with?...they said they would tell us when 3rd dosed (not drugged) and they have. They said 3rd because they probably knew this would be after the fundraise was completed. Keeping a bit of info up your sleeve for discussions with potential incestors was a commercial decision IMO...Avacta is a business and we have to appreciate that they won't tell us everything all the time.

'More potent warheads'..

Avacta did mention in an kld presentation slide that Dox mfrs would be their target market for AVA6000...this has changed to them keeping it and now I suspect their new target will be mfrs of more potent drugs.

'A number of patients remain on the three-weekly study at this time in several different cohorts.'

Amazing...

Kevin1977...here you go...

'Avacta receives approval to enrol patients in the UK in the ongoing two-weekly dose escalation study'

GeneralOz...they don't want a deal now for AVA6000...they want deals for the pipeline.

Get over it....move on...times have changed...

Timster...I'm not saying it doesn't hsppen just that it's not common for doctors to point patients to trials.

Yes side effects of chemo can be horrendous but the radiotherapy can be awful too.

Sorry to hear your SiL had such a bad time.

Kevin1977...I'm extremely sorry to hear about your friend. My advise is he should ask if there are any suitable trials available. If he doesn't feel comfortable with this route ( quite understandable) he should make sure his doctor gets him the fastest treatment possible. Don't let him be fobbed off. If he can't be treated quickly near to where he lives he should insist on going to other centres which can start treatment quickly and he should be prepared to travel. Speed is now priority. I wish him all the very best.

Timster...'He'd be given options of applicable trials from his physician when given the horrible prognosis.'

In my experience this is highly unlikely...doctors don't naturally point patients to trials. Patients who ask about trials may get pointed.

Thompi...thanks for your post...I'm posting it up again under a new heading just incase some missed it. It clearly explains why they are trying out a 2 weekly dose...it seems less could be more...

CC is referring to slide 13: Toxicities with AVA6000 Demonstrate a Dose Relationship

“And so this table then describes for you a critical observation, as it provides then our first evidence that using a lower dose, and potentially shortening the interval between doses to every two weeks could enhance the anti-tumour activity by delivering more drug, increasing the dose intensity but with little to no severe toxicity. There are examples of this kind of approach in the clinic. Probably the most relevant here is the taxane Paclitaxel in the field of oncology. When Paclitaxel is administered in some settings in an every three-week regimen at a higher dose it's highly toxic, it's effective. However, when it was moved to an every weekly regimen with a lower dose, the toxicity was minimised and actually enhanced the activity. This weekly regimen is used more in the clinic, both are still used. But this is the rationale for these new dose cohorts of every two weeks dosing and it's based on the observations in this slide.”

https://youtu.be/eqj0hhgmX6U?si=tER5X1gdtec3L9Cd

Hurst10...all these deals are for companies with more behind them than Avacta right now...be it sales, contracts, product pipelines in trial or commercialised. You're not comparing apples with apples.

Energyshares...yes I had read the Feb RNS and noted the plural tumour comment made by CC...

As AACR falls about 1 year from C5 dosing and will be through C7 and possibly beyond if they are continuing to dose those beyond the trial, I am hoping they will put some emphasis on OS.

The 2W trial has, IMHO, been introduced because of OS/observed tumour reductions/no MTD at 3 times normal Dox levels/limited side effects again at 3 times Dox levels.

Everyone knows Cancer is always a race against time...the longer the intervals between treatments the more chance the more chance of resistancy setting in which is the biggest problems combined with damage to other vial organs (heart being the major one in the case of Dox).

So...how will AVA6000 perform on a 2W basis...that's the next biggest factor in this very early stage SAFETY/DOSING trial and what new definitive data will they Post at AARC regading the 3W trial.

B2HS2L...No I was referring to OS...overall survival.

C5 first dose was April 23...

So my question is...are any of the patients still alive/in remission???? If so, this would be huge as they were all at end of life

B2HS2L...'IMO AACR info has to include Q3W data - cohorts 5,6, & 7, else why bother attending unless you are going to poster info that is publicly available from presentations.'

Sure it will. Even better if they are able to confirm patient(s) still surviving too...

'Monetising Diagnostics through divestment would also bring in non-dilutive funding, but may, in our view, be targeted for later in this period, giving management time to embed the acquisitions, and improve the sales and profitability trajectory. As usual in such situations, we suspend our valuation and forecasts; for context our last published Avacta valuation was £672m (equivalent to 237p per share).'

Gje306... in my experience it can take a few weeks before starting chemo...and as you say some patients may be nervous but they are not getting a new drug...they are getting dox in a new carrier which has already show it targets the dox at the tumour and substantially reduces the serious side effects.

It's more likely difficult to find patients that meet all the strict trial criteria...which is often the case with trials znd reason they can take longer than initially thought.

Gje306...the have said readouts are due late Q2..so June 2024. As I've said before they probably got all the screening sorted and were just waiting for the fundraiser to complete. Now they have to get their skates on...

Significant Newsflow

The Company is anticipating the progression of its clinical development and research stage programmes to important value inflection points across 2024 and 2025, which includes key deliverables for the pre|CISIONTM pipeline:

· AVA6000:

o Read out of two-weekly and three-weekly dose escalation study data in late Q2 2024;

o Presentation of Phase 1 three-weekly study clinical data at AACR 2024 in April 2024; and

o Establish recommended Phase 2 dose in Q3 2024, initiating the dose expansion phase in the US in H2 2024, followed by the Phase 2 study, subject to funding and FDA approval.

· AVA3996:

o Complete IND enabling studies and submit IND/CTA application in Q4 2024/Q1 2025; and

o Initiate Phase 1a dose escalation study in the first half of 2025.

· pre|CISION? pre-clinical pipeline:

o Next clinical candidate to be selected Q1 2025;

o Tumour microenvironment activated drug conjugate clinical candidate to selected in the second half of 2025; and

o Further expand pipeline;